BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DataCutoff//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DataCutoff · $MDGL readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by DataCutoff. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05500222-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:~Resmetirom readout (P3) · Madrigal Pharmaceuticals\, Inc. $MDGL
DESCRIPTION:A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinica
 l Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-
 OUTCOMES)\n\nPrimary completion date: 2026-12 (estimated) — month only\,
  shown on the 1st\nOriginally planned: 2025-08 (+16.0 months)\nPhase 3 · 
 Cardio-Met · NASH\, Cirrhosis\, Liver\nEnrollment: 845 · Sites: 141\n\nP
 rimary completion = last participant's primary-endpoint data collected\; t
 opline results usually follow weeks to months later. Sponsor-reported\, of
 ten an estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.ht
 ml?nct=NCT05500222\nhttps://clinicaltrials.gov/study/NCT05500222
URL:https://datacutoff.com/radar.html?nct=NCT05500222
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04951219-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:~Resmetirom readout (P3) · Madrigal Pharmaceuticals\, Inc. $MDGL
DESCRIPTION:A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom
  (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD)\, M
 AESTRO-NAFLD-Open-Label-Extension (MAESTRO-…\n\nPrimary completion date:
  2027-03 (estimated) — month only\, shown on the 1st\nOriginally planned
 : 2022-12 (+51.0 months)\nPhase 3 · Cardio-Met · Non-Alcoholic Fatty Liv
 er Disease\nEnrollment: 810 · Sites: 76\n\nPrimary completion = last part
 icipant's primary-endpoint data collected\; topline results usually follow
  weeks to months later. Sponsor-reported\, often an estimate. Not investme
 nt advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT04951219\nhttps://c
 linicaltrials.gov/study/NCT04951219
URL:https://datacutoff.com/radar.html?nct=NCT04951219
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
